Search - tctmd.com

Displaying 321 - 340 of 358

Sort: Relevancy | Date

News Conference News

RESET: Largest Study to Date of Xience, Cypher Shows Noninferiority

August 31, 2011

News Conference News

Long-term Antiplatelet Therapy: All Risk, No Benefit

August 30, 2011

News Conference News

New-Generation DES Reduce Restenosis, Stent Thrombosis

August 29, 2011

News Daily News

TRIAS HR Published: Genous Stent Doubles Target Lesion Failure

Leah Lawrence

August 23, 2011

News Daily News

No Apparent Advantage for Everolimus vs. Paclitaxel Stents in Diabetic Patients

L.A. McKeown

August 19, 2011

News Daily News

ESSENCE-DIABETES Published: Xience, Cypher Equally Equipped to Treat Diabetics

Caitlin E. Cox

August 03, 2011

News Daily News

Meta-analysis Finds Equivalence Between First-, Second-Generation DES

L.A. McKeown

August 02, 2011

News Daily News

Women Have Less Neointimal Hyperplasia Than Men With ZES

Leah Lawrence

July 29, 2011

News Daily News

ISAR-TEST 5 Published: Polymer-Free Dual DES Noninferior to Resolute

Jason Kahn

July 21, 2011

News Daily News

Cordis Announces Plans to Discontinue Cypher Stents, Drop Nevo Development

L.A. McKeown

June 15, 2011

News Daily News

RESOLUTE All Comers Looks at Simple, Complex Cases in Comparing ZES, EES

L.A. McKeown

June 10, 2011

News Industry News

Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System

May 25, 2011

News Daily News

EES Show Long-term Safety Advantage over SES

L.A. McKeown

May 24, 2011

News Industry News

Abbott Receives U.S. FDA Approval for XIENCE nano™ to Treat Coronary Artery Disease in Small Vessels

May 24, 2011

News Industry News

Medtronic Resolute® Drug-Eluting Stent Exhibits Strong Safety Profile in Broad Spectrum of Patients

May 20, 2011

News Industry News

Titanium-Nitride-Oxide Bio Active Technology in ACS Patients: Present and Future

May 18, 2011

News Industry News

A Prospective, Randomised and Multicentre Trial Comparing Titan2 Bio Active Stent (BAS) and Xience V Drug Eluting Stent (DES): The BASE-ACS Trial

May 17, 2011

News Daily News

Long-term Safety of PCI vs. CABG for Left Main Disease Depends on Syntax Score

May 16, 2011

News Daily News

Everolimus-Eluting Stents Found Equivalent to First-Generation Stents in Most Patients at 1 Year

Leah Lawrence

April 26, 2011

News Daily News

Two-Year Data Published from SPIRIT IV, COMPARE: Xience Still Favored Over Taxus

April 20, 2011

Advertisement

RESET: Largest Study to Date of Xience, Cypher Shows Noninferiority

Long-term Antiplatelet Therapy: All Risk, No Benefit

New-Generation DES Reduce Restenosis, Stent Thrombosis

TRIAS HR Published: Genous Stent Doubles Target Lesion Failure

No Apparent Advantage for Everolimus vs. Paclitaxel Stents in Diabetic Patients

ESSENCE-DIABETES Published: Xience, Cypher Equally Equipped to Treat Diabetics

Meta-analysis Finds Equivalence Between First-, Second-Generation DES

Women Have Less Neointimal Hyperplasia Than Men With ZES

ISAR-TEST 5 Published: Polymer-Free Dual DES Noninferior to Resolute

Cordis Announces Plans to Discontinue Cypher Stents, Drop Nevo Development

RESOLUTE All Comers Looks at Simple, Complex Cases in Comparing ZES, EES

Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System

EES Show Long-term Safety Advantage over SES

Abbott Receives U.S. FDA Approval for XIENCE nano™ to Treat Coronary Artery Disease in Small Vessels

Medtronic Resolute® Drug-Eluting Stent Exhibits Strong Safety Profile in Broad Spectrum of Patients

Titanium-Nitride-Oxide Bio Active Technology in ACS Patients: Present and Future

A Prospective, Randomised and Multicentre Trial Comparing Titan2 Bio Active Stent (BAS) and Xience V Drug Eluting Stent (DES): The BASE-ACS Trial

Long-term Safety of PCI vs. CABG for Left Main Disease Depends on Syntax Score

Everolimus-Eluting Stents Found Equivalent to First-Generation Stents in Most Patients at 1 Year

Two-Year Data Published from SPIRIT IV, COMPARE: Xience Still Favored Over Taxus

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content